Business Wire

CA-TRILINK-BIOTECH

Share
TriLink BioTechnologies® and Lonza Enter into Non-exclusive License and Supply Agreement for CleanCap® mRNA Capping Technology

TriLink BioTechnologies (TriLink®), a Maravai™ LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, has signed a non-exclusive License and Supply Agreement with Lonza, a global development and manufacturing partner to the pharma, biotech and nutrition industries. This agreement with Lonza strengthens TriLink’s objective to drive greater access to CleanCap® mRNA capping technologies as the demand for mRNA – a promising therapeutic modality – continues to grow.

According to the terms of the agreement, TriLink® will supply its patented CleanCap® M6, CleanCap® AG 3’OMe, CleanCap® AG, and CleanCap® AU cap analogs for use in Lonza’s global mRNA development and manufacturing services, from pre-clinical through Phase III programs. CleanCap® technology is a one-pot solution with over 95% capping efficiency that streamlines mRNA production processes when compared to legacy capping methods.

“CleanCap® technology is accelerating programs from discovery to the clinic via improved mRNA function, streamlined manufacturing, and maximized capped material yield,” shared Drew Burch, President of Nucleic Acid Production at TriLink. “We’re thrilled to offer our innovative capping solutions to Lonza and its customers.”

Since its launch in 2017, TriLink’s CleanCap® capping technology has continued to advance the mRNA capping industry and is used in a majority of approved mRNA and saRNA vaccines. In May 2023, TriLink introduced its most robust CleanCap analog to date, CleanCap® M6, with studies indicating increased mRNA expression by more than 30% versus enzymatic capping methods.

About TriLink BioTechnologies

TriLink BioTechnologies, a Maravai LifeSciences company, is a global leader in nucleic acid and mRNA solutions. TriLink delivers unrivaled chemical and biological experience, CDMO services, and high-quality readymade and custom materials, including its patented CleanCap® mRNA capping technology. Pharmaceutical leaders, biotech disruptors, and world governments depend on TriLink to meet their greatest challenges, from delivering the COVID-19 vaccine at warp speed, to empowering innovative treatments in oncology, infectious diseases, cardiology, and neurological disorders, to enabling future pandemic response plans.

For more information, visit trilinkbiotech.com.

About Maravai LifeSciences

Maravai is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics, and novel vaccines. Maravai’s companies are leaders in providing products and services in the fields of nucleic acid synthesis and biologics safety testing to many of the world’s leading biopharmaceutical, vaccine, diagnostics, and cell and gene therapy companies.

For more information about Maravai LifeSciences, visit maravai.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240430716807/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Europe’s First Meteorological Infrared Sounder Reveals the Atmosphere in 3D27.1.2026 10:30:00 CET | Press release

The first images from Europe’s pioneering meteorological infrared sounder were unveiled today at the EU Space Conference in Brussels, marking a major advance in the ability to monitor how the atmosphere evolves before and during severe weather. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260127490399/en/ Full Earth disc image from the MTG-S Infrared Sounder showing a surface-temperature-sensitive channel, captured between 12:45 and 15:30 UTC on 15 November 2025. The image distinguishes land and sea surface temperatures as well as cloud-top temperatures, highlighting cloud structures and weather systems. Hot desert regions appear in red, while cold cloud tops are shown in blue. © Image: Data acquired on 15 November 2025 and processed by industrial partners Thales and OHB under the supervision of EUMETSAT and ESA. Visual produced by EUMETSAT. The images were captured by the Infrared Sounder (IRS) flying aboard Meteosat Thir

Clearwater Analytics Embeds AI into Beacon Risk Platform to Accelerate Model Validation and Exposure Analysis27.1.2026 10:00:00 CET | Press release

Production-grade AI transforms quantitative workflows—from scenario analysis to tail risk modeling—inside investment risk operations engine Clearwater Analytics(NYSE: CWAN), the most comprehensive technology platform for investment management, today announced breakthrough embedded agentic AI capabilities within Beacon by CWAN, its enterprise risk and quantitative analytics platform, enabling risk teams to accelerate model validation, exposure analysis, and decision-making. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260126906084/en/ As regulatory scrutiny intensifies and portfolio complexity reaches unprecedented levels, traditional risk platforms are failing institutional investors when they need answers most. Built specifically for quantitative developers and risk professionals managing complex institutional portfolios, CWAN’s embedded AI operates within Beacon’s calculation engine itself, training the agents our client

Seasoned European Software Executive David Coste to Join Battery Ventures27.1.2026 09:00:00 CET | Press release

Coste, a longtime leader at pan-European ERP provider Forterro, will be a Battery executive-in-residence Battery Ventures, the global, technology-focused investment firm, announced it has hired former Forterro executive David Coste as an executive-in-residence based in its London office, effective next month. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260127122321/en/ David Coste, a former Forterro executive who begins a new executive-in-residence role with global investment firm Battery Ventures in London in February. At Battery, Coste will work closely with Battery Partner Zak Ewen and General Partner Morad Elhafed, among others, to help source and evaluate business-technology investments throughout Europe. Battery first opened its London office in 2016 and, since 2005, has completed more than 150 transactions across 13 countries including the U.K., Germany, France, the Netherlands, Belgium, Switzerland, Sweden and Nor

Castles Technology Partners With Loomis Pay to Power European Expansion With Next-Generation Android Devices27.1.2026 08:00:00 CET | Press release

Cutting-edge Android payment and Point-of-Sales (POS) technology set to transform the European payments and POS landscape Castles Technology, a global leader in Android payment acceptance devices, has been selected by Loomis Pay, the POS and digital payment division of Loomis, to support its European expansion. Through this collaboration, Loomis Pay will strengthen its capacity to deliver flexible and secure POS and payment solutions tailored to merchant preferences. As well as empowering merchants and their customers to transact the way they prefer, cash, card and digital. Following an extensive market review, Loomis Pay chose Castles Technology for its leadership in Android-based payment solutions, recognized for versatility, reliability, and innovation across its latest Android devices. Loomis Pay will deploy their POS and payment services on the portable S1F4 Pro, the PINPAD S1P2 and the unattended S1U2M4, as well its CasHUB TMS and Marketplace. Castles Technology and Loomis Pay ha

EIB Provides €20 Million in Financing to SamanTree Medical for Real-Time Microscopy for Surgical Procedures27.1.2026 07:00:00 CET | Press release

EIB-funding will accelerate development of the Histolog® Scanner and reinforce commercialisation efforts across Europe and United States SamanTree Medical, a European leader in surgical imaging innovation, has secured €20 million in financing from the European Investment Bank (EIB). The operation is backed by InvestEU, the EU’s flagship program to mobilize over €372 billion in additional investment from 2021 to 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260126080876/en/ The European Investment Bank (EIB) provides €20 million in financing to SamanTree Medical, a leader in surgical imaging innovation. The financing supports the development of an advanced confocal microscopy scanner for rapid imaging of the internal microstructure of tissue samples during surgical procedures, R&D and continued development and advancement of the company's Histolog® Scanner, the first and only medical imaging device featuring massively

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye